Next Article in Journal
The Evolving Role of Mucosal Histology in the Evaluation of Pediatric Functional Dyspepsia: A Review
Next Article in Special Issue
Role of Gastric Emptying in Symptoms of Gastroparesis
Previous Article in Journal
Histopathology of Barrett’s Esophagus and Early-Stage Esophageal Adenocarcinoma: An Updated Review
Open AccessArticle

Endoscopic Botulinum Toxin for Gastroparesis: Results of a Retrospective Series

Division of Gastroenterology and Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Gastrointest. Disord. 2019, 1(1), 164-175; https://doi.org/10.3390/gidisord1010012
Received: 25 September 2018 / Revised: 27 November 2018 / Accepted: 11 December 2018 / Published: 14 December 2018
(This article belongs to the Special Issue Gastroparesis)
Beneficial effects of pyloric botulinum toxin injection have been described in a subgroup of gastroparesis patients. Our aim is to evaluate whether clinical, manometric and/or scintigraphic parameters are able to predict treatment outcome. Forty patients (67% female, age 49 (36–56) years) with decompensated gastroparesis treated with botulinum toxin were included in this retrospective analysis. Objective parameters were high-resolution antroduodenal manometry, gastric emptying rate (scintigraphy), and weight change. Subjective treatment outcome was assessed with a Global Physician Assessment Scale. Binary logistic regression analysis was performed to identify predictors for treatment outcome. Fourteen patients (35%) were symptom-responders, and 65% of patients were short-term weight-responders. For both subjective and objective treatment outcome, no differences were found in manometric and scintigraphic variables between responders and non-responders. Neither clinical nor manometric or scintigraphic variables could predict subjective and objective treatment outcome. In conclusion, symptom improvement is achieved in a subgroup of gastroparesis patients treated with endoscopic pyloric botulinum toxin. Although the majority of patients were able to maintain their baseline weight at short-term follow-up, a substantial group of patients needed nutritional interventions on long-term follow-up. However, none of the demographic, clinical, scintigraphic, or antroduodenal manometry variables were able to predict either subjective or objective treatment outcome. View Full-Text
Keywords: antroduodenal manometry; gastric emptying; gastroparesis; botulinum toxin; endoscopy; endoscopic treatment antroduodenal manometry; gastric emptying; gastroparesis; botulinum toxin; endoscopy; endoscopic treatment
Show Figures

Figure 1

MDPI and ACS Style

Smeets, F.G.M.; Strijbos, D.; Keszthelyi, D.; Hoge, C.V.; Kruimel, J.W.; Conchillo, J.M.; Masclee, A.A. Endoscopic Botulinum Toxin for Gastroparesis: Results of a Retrospective Series. Gastrointest. Disord. 2019, 1, 164-175.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Back to TopTop